KR20110089184A - ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형 - Google Patents

２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형 Download PDF

Info

Publication number
KR20110089184A
KR20110089184A KR1020117014019A KR20117014019A KR20110089184A KR 20110089184 A KR20110089184 A KR 20110089184A KR 1020117014019 A KR1020117014019 A KR 1020117014019A KR 20117014019 A KR20117014019 A KR 20117014019A KR 20110089184 A KR20110089184 A KR 20110089184A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
weight
alkyl
release
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117014019A
Other languages
English (en)
Korean (ko)
Inventor
도미니코 파나라
프레데릭 엑크만
모니크 버웨어
Original Assignee
유씨비 파마, 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨비 파마, 에스.에이. filed Critical 유씨비 파마, 에스.에이.
Publication of KR20110089184A publication Critical patent/KR20110089184A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020117014019A 2008-11-18 2009-11-17 ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형 Ceased KR20110089184A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08105817.4 2008-11-18
EP08105817 2008-11-18
EP09100311 2009-06-02
EP09100311.1 2009-06-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000418A Division KR101788804B1 (ko) 2008-11-18 2009-11-17 ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형

Publications (1)

Publication Number Publication Date
KR20110089184A true KR20110089184A (ko) 2011-08-04

Family

ID=41395028

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117014019A Ceased KR20110089184A (ko) 2008-11-18 2009-11-17 ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형
KR1020177000418A Active KR101788804B1 (ko) 2008-11-18 2009-11-17 ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177000418A Active KR101788804B1 (ko) 2008-11-18 2009-11-17 ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형

Country Status (18)

Country Link
US (1) US8460712B2 (OSRAM)
EP (1) EP2358361B1 (OSRAM)
JP (2) JP5954889B2 (OSRAM)
KR (2) KR20110089184A (OSRAM)
CN (2) CN104083341A (OSRAM)
AU (1) AU2009317279B2 (OSRAM)
BR (1) BRPI0921301A2 (OSRAM)
CA (1) CA2741038C (OSRAM)
DK (1) DK2358361T3 (OSRAM)
EA (1) EA019583B1 (OSRAM)
ES (1) ES2602606T3 (OSRAM)
HK (1) HK1198288A1 (OSRAM)
HU (1) HUE030963T2 (OSRAM)
IL (1) IL212271A (OSRAM)
MX (1) MX356281B (OSRAM)
PL (1) PL2358361T3 (OSRAM)
PT (1) PT2358361T (OSRAM)
WO (1) WO2010057869A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057870A1 (en) * 2008-11-18 2010-05-27 Ucb Pharma, S.A. Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US20190125725A1 (en) * 2016-05-12 2019-05-02 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
ES3037587T3 (en) * 2021-05-11 2025-10-03 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
CN117355296A (zh) * 2021-05-11 2024-01-05 阿德维斯尼公司 用于口服施用舒噻美的延长释放药物组合物
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用
TR2023017170A1 (tr) * 2023-12-13 2025-06-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bri̇varasetam i̇çeren bi̇r saşe formülasyonu

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ES2294979T1 (es) * 2005-01-27 2008-04-16 Alembic Limited Formulacion de levetiracetam de liberacion prolongada.
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
EP1909770B1 (en) * 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
CN101111230B (zh) * 2005-03-29 2010-05-19 赢创罗姆有限责任公司 包含对活性成分具有调节释放作用的小丸的多颗粒药用形式
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
CN101506157B (zh) * 2006-06-08 2013-07-24 Ucb医药有限公司 吡咯烷酮共结晶
MX2009002166A (es) * 2006-08-31 2009-03-12 Eurand Inc Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
PL2187875T3 (pl) * 2007-09-21 2013-01-31 Evonik Roehm Gmbh Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu
DK2273975T3 (da) * 2008-03-03 2014-06-30 Ucb Pharma Sa Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser

Also Published As

Publication number Publication date
AU2009317279B2 (en) 2013-10-24
JP2012509356A (ja) 2012-04-19
CN104083341A (zh) 2014-10-08
JP5954889B2 (ja) 2016-07-20
KR20170007528A (ko) 2017-01-18
CA2741038A1 (en) 2010-05-27
EA201100753A1 (ru) 2012-01-30
IL212271A (en) 2016-10-31
HK1198288A1 (en) 2015-03-27
KR101788804B1 (ko) 2017-10-20
MX2011004572A (es) 2011-06-17
WO2010057869A1 (en) 2010-05-27
DK2358361T3 (en) 2016-12-12
US20110274762A1 (en) 2011-11-10
CA2741038C (en) 2015-01-13
CN102215828A (zh) 2011-10-12
HUE030963T2 (en) 2017-06-28
EP2358361B1 (en) 2016-09-14
IL212271A0 (en) 2011-06-30
MX356281B (es) 2018-05-22
PT2358361T (pt) 2016-11-18
JP2015143256A (ja) 2015-08-06
BRPI0921301A2 (pt) 2015-12-29
AU2009317279A1 (en) 2010-05-27
US8460712B2 (en) 2013-06-11
EA019583B1 (ru) 2014-04-30
ES2602606T3 (es) 2017-02-21
EP2358361A1 (en) 2011-08-24
PL2358361T3 (pl) 2017-02-28

Similar Documents

Publication Publication Date Title
KR101689688B1 (ko) ２­옥소­１­피롤리딘 유도체를 포함하는 지연 방출형 제형
US8563036B2 (en) Pharmaceutical compositions comprising Brivaracetam
KR101788804B1 (ko) ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형
EP2391351A1 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
HK1159503B (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
HK1159502A (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110617

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140626

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160406

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161017

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160406

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20161017

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160607

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20140626

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20161206

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161116

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20161017

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160607

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160406

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140626

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170105